These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12719860)

  • 1. [Antipruritic effects of pimecrolimus and tacrolimus].
    Ständer S; Luger TA
    Hautarzt; 2003 May; 54(5):413-7. PubMed ID: 12719860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
    Ständer S; Ständer H; Seeliger S; Luger TA; Steinhoff M
    Br J Dermatol; 2007 May; 156(5):1020-6. PubMed ID: 17388925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipruritic mechanisms of pimecrolimus cream for facial dermatitis in adult women patients].
    Xie ZQ; Yang GY; Jiang W; Xu ML
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):27-30. PubMed ID: 19317053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analgesic and antipruritic effects of oxymatrine sustained-release microgel cream in a mouse model of inflammatory itch and pain.
    Zhu T; Zhou D; Zhang Z; Long L; Liu Y; Fan Q; Chen F; Zhang X; Wu Y; Zeng H; Verkhratsky A; Zhao J; Nie H
    Eur J Pharm Sci; 2020 Jan; 141():105110. PubMed ID: 31654757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.
    Siepmann D; Lotts T; Blome C; Braeutigam M; Phan NQ; Butterfass-Bahloul T; Augustin M; Luger TA; Ständer S
    Dermatology; 2013; 227(4):353-60. PubMed ID: 24281309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis.
    Wollina U
    Am J Clin Dermatol; 2007; 8(3):157-73. PubMed ID: 17492844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pruritic diseases with topical calcineurin inhibitors.
    Ständer S; Schürmeyer-Horst F; Luger TA; Weisshaar E
    Ther Clin Risk Manag; 2006 Jun; 2(2):213-8. PubMed ID: 18360595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral tacrolimus treatment of pruritus in prurigo nodularis.
    Halvorsen JA; Aasebø W
    Acta Derm Venereol; 2015 Sep; 95(7):866-7. PubMed ID: 25804254
    [No Abstract]   [Full Text] [Related]  

  • 9. Off-label Uses of Topical Pimecrolimus.
    Ladda M; Sandhu V; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(4):442-448. PubMed ID: 31053034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
    Dattola A; Silvestri M; Bennardo L; Del Duca E; Longo C; Bianchi L; Nisticò S
    Dermatol Ther; 2018 Nov; 31(6):e12728. PubMed ID: 30295379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
    Goldstein AT; Thaçi D; Luger T
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):22-9. PubMed ID: 19631446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of atopic dermatitis in adults with topical calcineurin inhibitors].
    Meurer M; Wozel G
    Hautarzt; 2003 May; 54(5):424-31. PubMed ID: 12719862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.
    Stuetz A; Grassberger M; Meingassner JG
    Semin Cutan Med Surg; 2001 Dec; 20(4):233-41. PubMed ID: 11770910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis.
    Nakahara T; Morimoto H; Murakami N; Furue M
    Pediatr Allergy Immunol; 2018 May; 29(3):233-238. PubMed ID: 29205511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development and pre-clinical aspects of pimecrolimus].
    Stütz A; Grassberger M; Meingassner JG
    Hautarzt; 2003 May; 54(5):405-12. PubMed ID: 12719859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimecrolimus in dermatology: atopic dermatitis and beyond.
    Gisondi P; Ellis CN; Girolomoni G
    Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone.
    Inagaki N; Shiraishi N; Igeta K; Itoh T; Chikumoto T; Nagao M; Kim JF; Nagai H
    Eur J Pharmacol; 2006 Sep; 546(1-3):189-96. PubMed ID: 16914137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topical calcineurin inhibitors in atopic dermatitis.
    Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
    Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%.
    Fowler J; Johnson A; Chen M; Abrams K
    Cutis; 2007 Jan; 79(1):65-72. PubMed ID: 17330625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Hultsch T; Kapp A; Spergel J
    Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.